matt1926,,2019-05-21 15:50:00,3.761,BCLI more revenue to come and hopefully updates as treatment under HE continues great stuff
matt1926,,2019-05-21 15:49:00,3.761,BCLI The company recently announced an important milestone that the first three patients have been treated under the HE program In connection with treating those patients the company received approximately 1 million We anticipate approximately 3 patients being treated per month under the program and we estimate the company could report approximately 3 million in revenue for the second quarter of 2019 Updates on the patients treated through the HE program will occur as needed
sandyydarling,,2019-05-21 12:56:00,3.762,BCLI Full Report s1q4cdncom460208960file
sandyydarling,,2019-05-21 12:53:00,3.762,BCLI ConclusionBrainStorm has all the pieces in place to be successful including a worldclass management team sufficient capital to complete the Phase 3 ALS study and a data readout next year for an additional indication for NurOwn We estimate that if successful NurOwn could attain peak sales of 500 million in MS alone while in ALS we believe sales of 1 billion are possible Our valuation for BrainStorm is currently 17
sandyydarling,,2019-05-21 12:53:00,3.762,BCLI New research from Zacks analyst today Puts the minimum valuation at 17share
sandyydarling,,2019-05-21 12:50:00,3.762,BCLI scrzackscomNewsPressRe
